O
CBIO

OppenheimerFunds’s Crescent Biopharma CBIO Stock Holding History

OppenheimerFunds’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$59.3M Buy
47,601
+164
+0.3% +$188K 0.07% 273
2018
Q4 		$44.9M Buy
47,437
+3,216
+7% +$3.87M 0.06% 298
2018
Q3 		$63.7M Buy
44,221
+14,609
+49% +$22.1M 0.07% 280
2018
Q2 		$47.8M Buy
29,612
+4,563
+18% +$7.85M 0.06% 337
2018
Q1 		$40.7M Buy
+25,049
New +$52.1M 0.05% 371

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds's CBIO Position: Q1 2019 in Review

OppenheimerFunds increased its Crescent Biopharma (CBIO) stake by 0.35% in Q1 2019, buying an estimated $188K and bringing the position to 47,601 shares worth $59.3M. The position accounts for 0.07% of the portfolio, ranked #273.

OppenheimerFunds first reported a position in CBIO in Q1 2018 and has held it in 5 quarters since. The position peaked at $63.7M in Q3 2018. 77 funds tracked by Wall St. Rank hold CBIO as of Q1 2019.

  • OppenheimerFunds held 47,601 shares of Crescent Biopharma worth $59.3M as of Q1 2019.
  • OppenheimerFunds bought 164 Crescent Biopharma shares in Q1 2019, an estimated $188K.
  • Crescent Biopharma made up 0.07% of OppenheimerFunds's portfolio in Q1 2019, its #273 holding.
  • OppenheimerFunds first reported a position in Crescent Biopharma in Q1 2018 and has held it in 5 quarters since.
  • OppenheimerFunds's Crescent Biopharma position peaked at $63.7M in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.